Medipharm Labs Corp T.LABS

Avicanna financials released today Things looking up

[mdjbrown]

for companies competing in this sector

"Revenue growth of 314 per cent"


 https://www.stockwatch.com/News/Item/Z-C!AVCN-3531982/C/AVCN

[Olaf123]

Avcn end cash position year 2023: 477,198. End cash q3 2023: 718.287 December 4th: 2,537,508 ‎‎units of the Company (the “Units”) at a price of $0.35 per Unit for aggregate gross proceeds of $888,127.80 Each Unit is comprised of one common share in the capital of the Company (each, a “Unit Share”) and one-half of one (0.5) common share purchase warrant of the Company (each whole

[subaru1i]

Problem with your 'analysis' is that you cannot see their purchase orders or 'order books' that starting driving the high growth numbers reported today.   It's not a matter of 'cash' or 'burn rate', it's a matter of if AVCN wants to go it alone against other global pharma giants that already have distribution net works and shelf space in all major

[Olaf123]

What i'm saying is I speculate AVCN and MEDIF had discussion about M&A. They could not agree on the price. They both think they are undervalued. MEDIF knows they are really tight on money and might wait for a better deal. And we're doing that -- we're doing that on a licensing agreement perspective and looking at many deals with companies to do that, not in a full M&A